Rating Change
Piper Sandler reiterated its Neutral rating on Caris Life Sciences, Inc. (NASDAQ:CAI) on November 10, 2026.
reiterateNASDAQ:CAI
Piper Sandler Reiterates Neutral Rating on Caris Life Sciences, Inc. (CAI)
Piper Sandler reiterated its Neutral rating on Caris Life Sciences, Inc. (NASDAQ:CAI) on November 10, 2026.
At publication ·
What changed
Caris Life Sciences, Inc. (NASDAQ:CAI) · reiterate
- Firm
- Piper Sandler
- Rating
- Neutral to Neutral
- Price at event
- $24.43
- Market capitalization
- $7.5B
At a glance
Key takeaways
- Piper Sandler maintained a Neutral rating on Caris Life Sciences (CAI) on November 10, 2026, while the stock trades at $24.43 with a $7.5 billion market capitalization.
Market Context
Caris Life Sciences, Inc. operates in the Healthcare sector. The stock currently trades at $24.43 with a market capitalization of $7.5B. The stock has declined 4.6% over the past 52 weeks.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Caris Life Sciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Caris Life Sciences, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 10, 2026 | Piper Sandler | Neutral | N/A |
| Nov 06, 2026 | Citigroup | Buy | N/A |
| Nov 05, 2026 | TD Cowen | Buy | N/A |
| Nov 05, 2026 | BTIG | Buy | N/A |
| Oct 27, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CAI Stock Page
Frequently Asked Questions
What does the Neutral rating mean for CAI?
A rating of Neutral from Piper Sandler reflects the analyst's outlook on Caris Life Sciences, Inc. (NASDAQ:CAI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CAI forecast page.